Akribes Biomedical GmbH

Keywords

Chronic wounds, Drugs, Precision medicine, Wound exudate

What we investigate

Akribes Biomedical is dedicated to the improvement of chronic wound therapy. We develop “HealPredictor”, the first theranostic assay platform to enable personalized pharmacological therapy of chronic wounds. We identified drugs with so far unknown potential for chronic wound healing, which we want to develop as novel wound therapeutics.

Our research in more detail

Abbildung Akribes
Akribes assay platform: patient-specific ex vivo wound systems

Akribes Biomedical is developing the “HealPredictor” assay platform, which is designed to predict the response of individual chronic wound patients to pharmacological treatments. Our goal is to identify the right drug for the right patient. Akribes Biomedical is pursuing two linked objectives in parallel and in combination: 1) the development and implementation of the “HealPredictor” platform and 2) the development of new chronic wound therapies with “HealPredictor” as a companion theranostic.

Our unique entry point takes advantage of the fact that the pathogenic drivers of wound chronicity are contained in patient material. We showed that there is a causal link between wound chronicity and detrimental effects of wound exudates on primary human cell cultures and developed a panel of novel and IP-protected assay systems, which form the basis of our miniaturized, personalized, theranostic wound-on-a-chip assay panel. This includes cell types involved in the healing process, e.g. fibroblasts, keratinocytes, endothelial cells, and macrophages.

Using our assay platform for broad screening of compounds, Akribes Biomedical has not only identified compounds already used in wound healing, but also compounds representing two drug classes with so far unknown potential for treatment of chronic ulcers.

Selected publications

  • Dörfler P, Bauer W, Görge T, Luger T, Rappersberger K, Stingl G, Stockinger T, Stütz A, Wolff-Winiski B (2017) Comparative analysis of cytokines, proteases and growth factors in human wound exudates obtained by vacuum therapy.
    J Invest Dermatol 137, Suppl 1:S312.
  • Dörfler P, Stütz A, Wolff-Winiski B (2018) Effect of exogenous platelet-derived growth factor on the proliferation of human fibroblasts in the presence of human wound exudates.
    J Invest Dermatol 138, Suppl 1:S242.
  • Wolff-Winiski B, Fahrngruber H, Dörfler P, Schöfmann N, Stütz A (2018) Establishment of a pig model of delayed wound healing using human wound exudate.
    Exp Dermatol 27, Suppl 1:S13.